FeNO-Guided Asthma Treatment — board-level quick read

Personal study digest for IM boards. Recommendations are from the cited guideline; the “What’s changed” section is reviewer synthesis of newer evidence, each claim cited. Not a substitute for the full guideline.

Source digested: ATS 2021 Clinical Practice Guideline — Use of Fractional Exhaled Nitric Oxide (FeNO) to Guide the Treatment of Asthma (Dweik et al., Am J Respir Crit Care Med 2021; DOI; PMID 34779751)

In one line

FeNO >50 ppb flags T2/eosinophilic airway inflammation likely to respond to inhaled corticosteroids; the ATS conditionally recommends adding FeNO testing to usual care when contemplating asthma treatment changes — it reduces exacerbations (RR 0.72) but does not improve symptom scores or quality of life.

When to order FeNO

Asthma patients in whom a treatment change is being considered — starting, stepping up, or stepping down controller therapy.
Diagnostic uncertainty: FeNO ≥50 ppb supports eosinophilic/T2 asthma; <25 ppb argues against (but does not rule out) T2-driven disease.
Assessing ICS adherence: an unexpectedly high FeNO in a patient prescribed ICS suggests poor adherence or nonadherence rather than treatment failure.
Not a standalone test. Interpret alongside symptoms, spirometry, and clinical context.

How to interpret FeNO — adult thresholds

FeNO level	Interpretation	Action
<25 ppb	Low — eosinophilic inflammation unlikely	Consider non-T2 drivers (adherence, GERD, obesity, VCD). ICS step-down may be reasonable if well-controlled.
25–50 ppb	Intermediate — interpret with clinical context	Repeat testing, assess adherence, correlate with symptoms and spirometry.
>50 ppb	Elevated — eosinophilic inflammation likely	Start or step up ICS. If already on ICS, check adherence first. Consider biologic evaluation in severe asthma.

Cut-points from ATS 2011 interpretive guideline, adopted by the 2021 CPG. No specific FeNO “action thresholds” are endorsed — the framework uses pretest probability, not fixed cutoffs that mandate a specific change.

The guideline recommendation

Conditional recommendation — For patients with asthma in whom treatment is being contemplated, the ATS suggests FeNO-based care in addition to usual assessment (symptoms + spirometry), rather than usual assessment alone. Low confidence in estimates of effect.

Key effect estimates (FeNO-guided vs usual care)

Exacerbation rate: RR 0.72 (95% CI 0.56–0.93) — 111 fewer exacerbations per 1,000 patients
OCS courses: RR 0.79 (95% CI 0.65–0.95) — 69 fewer courses per 1,000
FEV₁: MD +1.11% predicted (95% CI 0.02–2.21) — statistically significant but clinically marginal
No improvement: ACT, ACQ-7, quality of life, symptom-free days, rescue inhaler use
Cost-effectiveness: Probably favors FeNO-based care (low certainty)

Key decisions an internist owns

FeNO is additive, not standalone. Always pair with symptoms, PFTs, and history. A low FeNO does not mean “no asthma” — non-eosinophilic phenotypes exist.
High FeNO + uncontrolled asthma on ICS → check adherence and inhaler technique before escalating. FeNO drops rapidly with ICS adherence.
Confounders that raise FeNO: atopy, rhinitis, eosinophilic bronchitis, dietary nitrate. Lower FeNO: smoking, bronchoconstriction, recent spirometry effort.
Not validated for COPD management. GOLD uses blood eosinophil count, not FeNO, to guide ICS in COPD. FeNO >50 ppb in a COPD patient raises suspicion for asthma–COPD overlap.

Special populations

Pregnancy: The Breathing for Life Trial (n = 1,200) found FeNO-guided asthma management did not improve perinatal outcomes vs usual care.⁵
Obesity: FeNO may be lower in obese patients independent of inflammation — use caution interpreting low values.
Smokers: Active smoking suppresses FeNO; thresholds may need lowering (some guidelines use <15 ppb as “low” in smokers).

What’s changed since 2021

Reviewer synthesis — not the guideline.

Core recommendation confirmed. A 2024 updated systematic review and meta-analysis (13 RCTs, adults) confirmed FeNO-guided management reduces exacerbations vs conventional care. No improvement in severe exacerbations requiring OCS/hospitalization, FEV₁, or QoL — consistent with the 2021 findings. Tsurumaki et al., Respir Investig 2024; DOI; PMID 39689589
GINA 2025 — T2 biomarker appendix. GINA now includes a dedicated appendix on T2 biomarkers. High FeNO supports ICS initiation or step-up; low FeNO should not prevent ICS when clinically indicated. FeNO also aids biologic selection: elevated baseline FeNO predicts greater response to anti-IL-4Rα and anti-IL-13 agents.³
Biologics era — FeNO predicts response. The VESTIGE trial (phase 4 RCT, n = 109) showed dupilumab reduced FeNO to <25 ppb in 57% of patients vs 11% placebo at 24 weeks, with corresponding reductions in mucus plugging and improved airway volume. Baseline FeNO is now recognized as a predictor of biologic response, particularly for dupilumab and tezepelumab.⁴
BTS/NICE/SIGN 2024 joint guideline. The November 2024 UK guideline endorses FeNO ≥50 ppb as a diagnostic aid for asthma in adults and recommends checking FeNO when asthma is uncontrolled (may indicate poor ICS adherence).⁶
Still current: The <25 / 25–50 / >50 ppb cut-point framework remains the international standard — adopted unchanged by GINA 2025 and BTS/NICE/SIGN 2024.
Open — action thresholds undefined. No post-2021 study has resolved which specific FeNO value should trigger a specific treatment change. The framework remains probabilistic, not prescriptive.

Anki cards minted this run

FeNO cut-points in adults — the three-tier ATS framework (<25 / 25–50 / >50 ppb)
What FeNO-guided asthma care reduces — exacerbations (RR 0.72), not symptom scores or QoL
What elevated FeNO indicates — T2/eosinophilic airway inflammation; predicts ICS and biologic responsiveness
FeNO confounders — what raises vs lowers FeNO (smoking, atopy, bronchoconstriction)

Sources

[1] Dweik RA, et al. An Official ATS Clinical Practice Guideline: Use of Fractional Exhaled Nitric Oxide (FeNO) to Guide the Treatment of Asthma. Am J Respir Crit Care Med 2021;204(10):e97–e109. DOI. PMID 34779751.
[2] Dweik RA, et al. An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. Am J Respir Crit Care Med 2011;184(5):602–615. DOI. PMID 21885636.
[3] Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2025 Update. ginasthma.org.
[4] Castro M, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in type 2 asthma (VESTIGE). Lancet Respir Med 2025;13(3):208–220. DOI. PMID 39947221.
[5] Murphy VE, et al. Effect of asthma management with exhaled nitric oxide vs usual care on perinatal outcomes (Breathing for Life Trial). Eur Respir J 2022;60(5):2200298. DOI. PMID 35777773.
[6] British Thoracic Society / NICE / SIGN. British guideline on the management of asthma, November 2024 update. BTS.
[7] Tsurumaki H, et al. Assessing the utility of FeNO-guided management in adult patients with asthma: a systematic review and meta-analysis. Respir Investig 2024;63(1):118–126. DOI. PMID 39689589.